About Stevanato Group S.p.A. Ordinary Shares (STVN)
Stevanato Group S.P.A. is a global leader in the design and manufacturing of drug containment and delivery solutions for the pharmaceutical and biotechnology industries. The company specializes in producing high-quality glass vials, syringes, and other packaging solutions that ensure the safe and effective delivery of medicines. Additionally, Stevanato Group offers integrated technologies and services, focusing on enhancing the performance of its products through innovative packaging systems and automation processes. The company’s commitment to quality, safety, and sustainability makes it a trusted partner for healthcare organizations seeking reliable and efficient solutions for their drug delivery needs. Read More
Shares of West Pharmaceutical Services (NYSE: WST) tumbled 5.7% on Tuesday following the announcement that Eric Green, the company’s President, Chief Executive Officer, and Chair of the Board, intends to retire. The decline, which wiped out significant market capitalization in a single session, reflects investor anxiety over the
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and full year 2025.
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the fourth quarter and fiscal year 2025 on Wednesday, March 4, 2026, at 6:30 a.m. (ET).
Date: December 23, 2025 Introduction In the high-stakes world of biotechnology and pharmaceutical manufacturing, few companies are as indispensable yet as quietly influential as West Pharmaceutical Services (NYSE: WST). Headquartered in Exton, Pennsylvania, West is a global leader in the design and production of technologically advanced containment and delivery systems for injectable drugs. While the [...]
As the pharmaceutical industry undergoes its most significant transformation in decades, the spotlight often falls on the blockbuster drugs themselves—the weight-loss miracles and the life-saving biologics. However, a quieter, equally vital revolution is happening in the delivery systems that bring these treatments to patients. West Pharmaceutical Services (NYSE: WST)
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2025.
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will participate in two upcoming investor conferences.
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2025 on Thursday, November 6, 2025, at 6:30 a.m. (ET).
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced a significant expansion of its drug delivery system manufacturing capacity, further strengthening its global footprint to meet the industry’s evolving needs.
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will participate in two upcoming investor conferences.
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2025.
Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it has secured €200 million in financing through agreements with BNL BNP Paribas, Cassa Depositi e Prestiti (CDP), and Banco BPM. These fundings are intended to support the Company’s ongoing capital expenditure projects in Cisterna di Latina (Italy) and Fishers (Indiana, U.S.).
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2025 on Tuesday, August 5, 2025, at 6:30 a.m. (ET).
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will participate in three upcoming investor conferences.
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2025.
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2025 on Thursday, May 8, 2025, at 6:30 a.m. (ET).
